Plain-English translation of NCT03317158 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether durvalumab and other immune-boosting medications can help treat bladder cancer that has not responded well to standard BCG treatment or has come back after BCG. The study is organized in two phases: Phase 1 tests the safety and best doses of different drug combinations, and Phase 2 expands testing of the combinations that work best. The goal is to find new options for people whose cancer hasn't responded to existing treatments.
Some patients with non-muscle invasive bladder cancer don't respond well to the current standard treatment (BCG), and others experience cancer recurrence even after treatment. This trial exists to develop new immune-based treatment options for these patients who have limited alternatives.
Participation involves receiving one of several treatment combinations, which may include intravenous infusions, medications placed directly into the bladder, external beam radiation, or a combination of these approaches. The exact treatment and schedule will depend on which study group you are assigned to and which phase of the trial is open when you enroll. You will have regular clinic visits for treatment administration, safety monitoring, and imaging tests to assess how your cancer is responding.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.